Atomic mass

First Phosphate Drills a 2 m Vein of Massive Apatite at Its Begin-Lamarche Project in Saguenay-Lac-St-Jean, Quebec, Canada

Retrieved on: 
Tuesday, April 2, 2024
Saguenay, Apatite, Phosphate, OTC, See, Atomic mass, PO4, Critical, Road

In total 16,435 m of drilling have been completed to date and assays have now been returned for 5,642 m since drilling began in February 2024.

Key Points: 
  • In total 16,435 m of drilling have been completed to date and assays have now been returned for 5,642 m since drilling began in February 2024.
  • Phosphate Mountain Zone: Hole BL-24-82 intersected 2 m of massive apatite while other drill holes in this zone continued to yield core results of 30%+ apatite.
  • "The Mountain and Northern Zones show high-grade phosphate on surface while the Southern Zone shows large tonnage potential over a strike length of 1.5 km."
  • Apatite is very common as an accessory mineral in igneous and metamorphic rocks where it is the most common phosphate mineral form to be found.

Alpine Immune Sciences Presents New Translational Data on Povetacicept at the European Lupus Meeting 2024

Retrieved on: 
Thursday, March 21, 2024
Biotechnology, Pharmaceutical, Health, Clinical Trials, IgA nephropathy, Brain, Isoelectric point, WT, Lupus, Patient, Lung, Tissue, Immunoglobulin A, SLE, Doctor of Philosophy, Inflammation, MD, Skin, Alpine, Kidney, Technical, Atomic mass, Autoimmunity, ALPN, Pharmaceutical industry

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.

Key Points: 
  • Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced today that the Company presented new translational data for povetacicept (ALPN-303) at the SLEuro 14th European Lupus Meeting in Bruges, Belgium, March 19-22, 2024.
  • BAFF- and APRIL-related genes are increased in myeloid and B cells in systemic lupus erythematosus (SLE) patients compared to healthy adults.
  • Povetacicept significantly reduces multiple disease parameters in the NZB/W mouse model of lupus, more effectively than WT TACI-Ig or B cell depletion.
  • These findings are particularly intriguing considering that these organs are of particular relevance to our lead indications, systemic lupus erythematosus and IgA nephropathy.

Beyoncé Knowles-Carter Introduces Cécred: Hair-Honoring Care, Validated by Science

Retrieved on: 
Tuesday, February 20, 2024
Philosophy, Professional, LOS, Entrepreneurship, Atomic mass, Education, Silicone, Life, Scalp, Honey, Collection, Safety, Tea tree oil, Perspiration, Protein, Knowledge, Oil, Fermentation, Research, Water, Cosmetics

LOS ANGELES, Feb. 20, 2024 /PRNewswire/ -- Beyoncé Knowles-Carter announced the launch of Cécred, a new haircare line that honors global traditions while delivering what hair craves: rich conditioners and fortifying protein, patent-pending technology and fermentation, sensorial luxury and exceptional performance for visible strength, moisture and shine. Inspired by hair rituals from global cultures, the products feature an array of butters, oils, honey, and fermented rice water to nourish hair. Cécred launches with the Foundation Collection, eight products that cleanse, condition, and visibly repair.

Key Points: 
  • "The journey of creating Cécred has taken years, and I'm so proud to finally reveal what we've been working on," says Cécred founder and chairwoman Beyoncé Knowles-Carter.
  • My entire life and career, I've worn my hair in so many different ways: natural, flat-ironed, braids, colored, weaves, wigs.
  • Our patent-pending technology, made from wool-derived keratin, honey, and lactobacillus ferment, closely matches and replaces depleted proteins in hair.
  • Its molecular weight is small enough to deeply penetrate the cortex to visibly strengthen weak, damaged, or highly manipulated hair.

Beyoncé Knowles-Carter Introduces Cécred: Hair-Honoring Care, Validated by Science

Retrieved on: 
Tuesday, February 20, 2024
Philosophy, Professional, LOS, Entrepreneurship, Atomic mass, Education, Silicone, Life, Scalp, Honey, Collection, Safety, Tea tree oil, Perspiration, Protein, Knowledge, Oil, Fermentation, Research, Water, Cosmetics

LOS ANGELES, Feb. 20, 2024 /PRNewswire/ -- Beyoncé Knowles-Carter announced the launch of Cécred, a new haircare line that honors global traditions while delivering what hair craves: rich conditioners and fortifying protein, patent-pending technology and fermentation, sensorial luxury and exceptional performance for visible strength, moisture and shine. Inspired by hair rituals from global cultures, the products feature an array of butters, oils, honey, and fermented rice water to nourish hair. Cécred launches with the Foundation Collection, eight products that cleanse, condition, and visibly repair.

Key Points: 
  • "The journey of creating Cécred has taken years, and I'm so proud to finally reveal what we've been working on," says Cécred founder and chairwoman Beyoncé Knowles-Carter.
  • My entire life and career, I've worn my hair in so many different ways: natural, flat-ironed, braids, colored, weaves, wigs.
  • Our patent-pending technology, made from wool-derived keratin, honey, and lactobacillus ferment, closely matches and replaces depleted proteins in hair.
  • Its molecular weight is small enough to deeply penetrate the cortex to visibly strengthen weak, damaged, or highly manipulated hair.

Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting

Retrieved on: 
Wednesday, February 7, 2024
Oncology, Health, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, Neoplasm, Acute myeloid leukemia, Permeability, Patient, ASCO, MD Anderson Cancer Center, AML, Myelodysplastic syndrome, Marketing, PEG, MDS, DDS, Blood, Spacecraft, Colorectal cancer, University, Cancer, Atomic mass

in 2024, we are excited to share our latest development status.

Key Points: 
  • in 2024, we are excited to share our latest development status.
  • A Phase I clinical dose-finding study of DFP-14927 in patients with solid tumors has been completed at MD Anderson Cancer Center and the University of California, Los Angeles in the United States.
  • Subsequently, the concentration of DFP-10917, the active component of DFP-14927, delivering into cancer tissue in patients treated with DFP-14927 is being measured to confirm PK/PD relationship for the clinical efficacy of DFP-14927.
  • On 6th Feb. 2024, we are pleased to announce that we have submitted an abstract to the 2024 ASCO annual meeting to be held from May 31st this year in Chicago.

Enterprise Therapeutics Closes £26 million ($33.1 million) Series B Follow-on Financing

Retrieved on: 
Tuesday, January 30, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Urinary tract infection, Chronic obstructive pulmonary disease, CFTR, Mortality, FEV1, Respiratory disease, Therapy, Disease, Patient, Enterprise, Mucus, IP Group, Cystic fibrosis, Epithelial sodium channel, Asthma, Atomic mass

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.

Key Points: 
  • Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering from respiratory disease, today announced that it has closed a £26 million ($33.1 million USD) Series B follow-on financing round, led by Panakes Partners.
  • Existing investors Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital and IP Group also participated.
  • Alongside the financing, Dr Rob Woodman, Partner at Panakes, joins Enterprise’s Board of Directors.
  • Dr John Ford, CEO, Enterprise Therapeutics, said: “We have made tremendous progress to date in developing novel therapeutics for patients suffering from chronic respiratory diseases.

PacBio Announces New Nanobind PanDNA Kit Enabling HiFi Optimized DNA Extraction Solutions

Retrieved on: 
Monday, January 15, 2024
Research, Animal, DNA, CBB, Atomic mass, Tree, Compatibility, Abraxis BioScience, Cell, Bacteria, High fidelity, Medical research, Plant, Fungus, Wellcome Sanger Institute, Blood

MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read sequencing, including cells, bacteria, blood, tissue, plant nuclei, and insects.

Key Points: 
  • MENLO PARK, Calif., Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit.
  • Nanobind kits are designed for researchers to efficiently extract high-quality, high molecular weight DNA across a wide range of sample types.
  • These kits are versatile, accommodating both manual (Nanobind PanDNA kit) and high-throughput (Nanobind CBB HT kit) settings.
  • "The new PanDNA kit will be the go-to kit for extracting DNA optimized for HiFi sequencing," said Jeff Eidel, Chief Commercial Officer at PacBio.

Unchained Labs rolls out the red carpet for the king of LNP characterization…Stunner!

Retrieved on: 
Tuesday, January 9, 2024
Vivisection, Protein, Atomic mass, Marketing, LNP, UV, SVP, Fine chemical

Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.

Key Points: 
  • Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.
  • In the same 2-minute experiment it uses UV/Vis with precision of 1% and accuracy of 2% to quantify the total payload present.
  • "Our new Stunner really is the cream of the crop for LNP characterization.
  • It measures exactly what researchers need to find the best formulation and develop a robust process to make great LNPs," said Taegen Clary, SVP of Marketing at Unchained Labs.

Unchained Labs rolls out the red carpet for the king of LNP characterization…Stunner!

Retrieved on: 
Tuesday, January 9, 2024
Vivisection, Protein, Atomic mass, Marketing, LNP, UV, SVP, Fine chemical

Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.

Key Points: 
  • Enter Stunner, the first instrument to pull all this LNP data together from one tiny 2 µL sample.
  • In the same 2-minute experiment it uses UV/Vis with precision of 1% and accuracy of 2% to quantify the total payload present.
  • "Our new Stunner really is the cream of the crop for LNP characterization.
  • It measures exactly what researchers need to find the best formulation and develop a robust process to make great LNPs," said Taegen Clary, SVP of Marketing at Unchained Labs.

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

Retrieved on: 
Thursday, January 4, 2024
Receptor (biochemistry), EST, Conference, C5a, Aes, Biotechnology, BID, Cmax, MD, Conference call, PD, Food, SAD, Patient, Safety, Therapy, Atomic mass, Pharmaceutical industry

INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.

Key Points: 
  • INF904 was well tolerated and there were no adverse safety events of concern after repeated dosing in participants over the entire tested dose range.
  • “We are very pleased that the MAD part of the Phase I study exceeded the already compelling results from the SAD part of the study.
  • InflaRx currently plans to initiate a short-term dosing Phase II study towards the end of 2024, followed by a longer-term dosing Phase II study in 2025.
  • A replay will be available on the InflaRx website in the Investors – Events & Presentations section after the live conference call has concluded.